Study validates Matritech's bladder cancer test
This article was originally published in Clinica
Executive Summary
Matritech's NMP22 BladderChek Test can detect cancers missed by cystoscopy - the reference standard used to diagnose bladder cancer, according to a study published in the Journal of the American Medical Association (JAMA) (February 16). The American Cancer Society says that approximately 13,000 people in the US will die from bladder cancer in 2005.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.